$2.80
0.02[0.72%]
At close: Apr 18
$2.80
0[0.00%]
PreMarket: 7:05AM EDT
Arbutus Biopharma
(NASDAQ:ABUS)Arbutus Biopharma Stock (NASDAQ:ABUS), Analyst Ratings, Price Targets, Predictions
Arbutus Biopharma Corp has a consensus price target of $5.4, established from looking at the 23 latest analyst ratings. The last 3 analyst ratings were released from JMP Securities, Chardan Capital, and HC Wainwright & Co. on April 4, 2024, March 1, 2024, and March 1, 2024. With an average price target of $4.33 between JMP Securities, Chardan Capital, and HC Wainwright & Co., there's an implied 54.76% upside for Arbutus Biopharma Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Chardan Capital
HC Wainwright & Co.
Jefferies
JMP Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Arbutus Biopharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/04/2024 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 42.86% | JMP Securities | Roy Buchanan | → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/01/2024 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 42.86% | Chardan Capital | Keay Nakae | → $4 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 78.57% | HC Wainwright & Co. | Ed Arce | $6 → $5 | Maintains | Buy | Get Alert |
| 09/12/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | Chardan Capital | Keay Nakae | → $6 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | JMP Securities | Roy Buchanan | → $6 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/22/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | Chardan Capital | Keay Nakae | → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | → Buy | Get Alert |
| 04/28/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | → Buy | Get Alert |
| 04/05/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | → Buy | Get Alert |
| 03/29/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | JMP Securities | Roy Buchanan | → $6 | Reiterates | → Market Outperform | Get Alert |
| 03/20/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | HC Wainwright & Co. | Ed Arce | → $6 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | Chardan Capital | Keay Nakae | → $6 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | HC Wainwright & Co. | Ed Arce | → $6 | Maintains | Buy | Get Alert |
| 11/10/2022 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 114.29% | HC Wainwright & Co. | Ed Arce | $7.5 → $6 | Maintains | Buy | Get Alert |
| 06/28/2022 | ABUS | Buy Now | Arbutus Biopharma | $2.80 | 221.43% | JMP Securities | Roy Buchanan | $10 → $9 | Maintains | Market Outperform | Get Alert |
FAQ
What is the target price for Arbutus Biopharma (ABUS)?
The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by JMP Securities on April 4, 2024. The analyst firm set a price target for $4.00 expecting ABUS to rise to within 12 months (a possible 42.86% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arbutus Biopharma (ABUS)?
The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by JMP Securities, and Arbutus Biopharma reiterated their market outperform rating.
When was the last upgrade for Arbutus Biopharma (ABUS)?
The last upgrade for Arbutus Biopharma Corp happened on February 2, 2022 when Jefferies raised their price target to $5. Jefferies previously had a hold for Arbutus Biopharma Corp.
When was the last downgrade for Arbutus Biopharma (ABUS)?
There is no last downgrade for Arbutus Biopharma.
When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on April 4, 2024 so you should expect the next rating to be made available sometime around April 4, 2025.
Is the Analyst Rating Arbutus Biopharma (ABUS) correct?
While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $4.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.80, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.